Dr. Roy received his Ph.D. from the University of Massachusetts (1976) and did his postdoctoral training at The Rockefeller University (1976-1979). He is an Affiliate in the Department of Molecular and Integrative Physiology, a Professor of Pathology, and a Professor of Neuroscience at the University of Illinois.
Dr. Roy’s research team is committed to developing immunotherapies for brain tumors that are effective and selective. They use mice as experimental subjects because much is known about their immune system, and the murine system closely parallels the human immune system. When properly activated, the immune system has the characteristics of an ideal therapy: potent, precise killing of altered cells. But there is much to be learned about how to activate, direct, and control the immune response, particularly against tumors within the brain. They focus mostly on T cell mediated immune responses, and work in close collaboration with the laboratory of David Kranz, a T cell biochemist.
Glioma, brain tumor, melanoma, immunotherapy, adoptive T cell therapy
Visit http://mcb.illinois.edu/faculty/profile/eroy to learn more about Dr. Roy, including publication information.